Keen global interest in the development of new drug modalities is being reflected in the trends of R&D support granted by a major South Korean state-run fund.
This year, areas such as antibody-drug conjugates (ADC) and targeted protein degradation (TPD) stood out in the Korea Drug Development Fund’s (KDDF) grant selection process, while oncology and discovery-stage projects
Key Takeaways
Oncology and discovery-stage assets have accounted for the majority of projects selected for R&D grants by a Korean state-run fund this year, while new drug modalities such as ADC and TPD were much more noticeable.
This trend is in line with the country's key national technology policy, which includes AI-based, innovative drug development projects, development of digital convergence biotechnology, as well as new drug modalities
